BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

328 related articles for article (PubMed ID: 20526105)

  • 1. Molecular markers in the treatment of metastatic colorectal cancer.
    Wilson PM; Labonte MJ; Lenz HJ
    Cancer J; 2010; 16(3):262-72. PubMed ID: 20526105
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Integrating biomarkers into clinical decision making for colorectal cancer.
    Wilson PM; Lenz HJ
    Clin Colorectal Cancer; 2010 Jun; 9 Suppl 1():S16-27. PubMed ID: 20630847
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular predictors of response to chemotherapy in colorectal cancer.
    Dienstmann R; Vilar E; Tabernero J
    Cancer J; 2011; 17(2):114-26. PubMed ID: 21427555
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recent advances in personalized colorectal cancer research.
    Kraus S; Nabiochtchikov I; Shapira S; Arber N
    Cancer Lett; 2014 May; 347(1):15-21. PubMed ID: 24491406
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacogenomics and -genetics in colorectal cancer.
    Pohl A; Lurje G; Manegold PC; Lenz HJ
    Adv Drug Deliv Rev; 2009 May; 61(5):375-80. PubMed ID: 19100300
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Integration of anti-epidermal growth factor receptor therapies with cytotoxic chemotherapy.
    Serrano C; Markman B; Tabernero J
    Cancer J; 2010; 16(3):226-34. PubMed ID: 20526101
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Biomarker for chemotherapy in patients with colorectal cancer].
    Matsusaka S
    Gan To Kagaku Ryoho; 2009 Jan; 36(1):11-4. PubMed ID: 19151559
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of anti-epidermal growth factor receptor monoclonal antibody monotherapy in the treatment of metastatic colorectal cancer.
    Bouché O; Beretta GD; Alfonso PG; Geissler M
    Cancer Treat Rev; 2010 Feb; 36 Suppl 1():S1-10. PubMed ID: 20189053
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Individualized therapy in non-small-cell lung cancer: future versus current clinical practice.
    Pérez-Soler R
    Oncogene; 2009 Aug; 28 Suppl 1():S38-45. PubMed ID: 19680295
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel agents in the treatment of metastatic colorectal cancer.
    Leong S; Messersmith WA; Tan AC; Eckhardt SG
    Cancer J; 2010; 16(3):273-82. PubMed ID: 20526106
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New strategies for treatment of KRAS mutant metastatic colorectal cancer.
    Prenen H; Tejpar S; Van Cutsem E
    Clin Cancer Res; 2010 Jun; 16(11):2921-6. PubMed ID: 20460490
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of molecular biomarkers in individualized treatment of colorectal cancer.
    De Mattos-Arruda L; Dienstmann R; Tabernero J
    Clin Colorectal Cancer; 2011 Dec; 10(4):279-89. PubMed ID: 21729679
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictive markers for colorectal cancer: current status and future prospects.
    Longley DB; McDermott U; Johnston PG
    Clin Colorectal Cancer; 2003 Feb; 2(4):223-30. PubMed ID: 12620141
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Progress and challenges in the identification of biomarkers for EGFR and VEGFR targeting anticancer agents.
    Le Tourneau C; Vidal L; Siu LL
    Drug Resist Updat; 2008 Jun; 11(3):99-109. PubMed ID: 18515176
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biomarkers of Resistance to Epidermal Growth Factor Receptor Monoclonal Antibodies in Patients with Metastatic Colorectal Cancer.
    Banck MS; Grothey A
    Clin Cancer Res; 2009 Dec; 15(24):7492-7501. PubMed ID: 20008849
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Colorectal cancer in review: the role of the EGFR pathway.
    Saif MW
    Expert Opin Investig Drugs; 2010 Mar; 19(3):357-69. PubMed ID: 20095919
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epidermal growth factor receptor inhibitors in cancer treatment: advances, challenges and opportunities.
    Modjtahedi H; Essapen S
    Anticancer Drugs; 2009 Nov; 20(10):851-5. PubMed ID: 19826350
    [TBL] [Abstract][Full Text] [Related]  

  • 19. What is the role and impact of molecular markers on treatment decisions for colorectal cancer in the adjuvant setting?
    Al-Salama HM; Johnstone EC; Kerr DJ
    Discov Med; 2009 Oct; 8(42):104-7. PubMed ID: 19833054
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting signal transduction pathways in colorectal cancer--more than skin deep.
    Cohen SJ; Cohen RB; Meropol NJ
    J Clin Oncol; 2005 Aug; 23(23):5374-85. PubMed ID: 15998904
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.